Elucid Raises $55M to Expand AI Cardiovascular Diagnostics
Elucid Raises $55M Series D Funding Boston-based medical technology company Elucid has raised $55 million in fresh funding. The company secured the capital through an oversubscribed Series D financing round. The post Elucid Raises $55M to Expand AI Cardiovascular Diagnostics appeared first on Ventureburn .
Boston-based medical technology company Elucid has raised $55 million in a Series D funding round. This brings the company's total funding to approximately $185 million. IAG Capital Partners and Elevage Medical Technologies, created by Patient Square Capital, have joined as new strategic investors, making Elucid the fourth publicly traded strategic investor.
The new investment indicates renewed industry faith in Elucid's cardiovascular technology. Leveraging AI, Elucid is developing software to assist clinicians in diagnosing and managing cardiovascular diseases. The company's Plaque-IQ technology is FDA-cleared and quantifies dangerous plaque in coronary and carotid arteries. The BioIntegrated FFR-CT product, currently in FDA clearance with 510(k) submissions, will help determine coronary blockage.
Elucid is integrating FFR-CT with Plaque-IQ, aiming to create a comprehensive clinical decision system to quantify cardiovascular risk. The company is on track for a commercial launch of BioIntegrated FFR-CT, which will combine with Plaque-IQ to provide personalized cardiovascular disease treatment. Atherosclerotic cardiovascular disease remains a major global health challenge, and Elucid aims to address this burden through non-invasive imaging technology.
The latest funding will bolster Elucid's clinical platform, regulatory progress, and strategic medtech partnerships, signaling increasing confidence in AI-powered cardiovascular diagnostics.
Written by urgent.news from Ventureburn's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
